Efficacy, safety, and tolerability of overnight switching from immediate‐ to once daily extended‐release pramipexole in early Parkinson's disease
Identifieur interne : 001702 ( Istex/Curation ); précédent : 001701; suivant : 001703Efficacy, safety, and tolerability of overnight switching from immediate‐ to once daily extended‐release pramipexole in early Parkinson's disease
Auteurs : Olivier Rascol [France] ; Paolo Barone [Italie] ; Robert A. Hauser [États-Unis] ; Yoshikuni Mizuno [Japon] ; Werner Poewe [Autriche] ; Anthony H. V. Schapira [Royaume-Uni] ; Laurence Salin [France] ; Mandy Sohr [Allemagne] ; Catherine Debieuvre [France]Source :
- Movement Disorders [ 0885-3185 ] ; 2010-10-30.
English descriptors
Abstract
The aim of this article is to test the feasibility, in early Parkinson's disease (PD), of an overnight switch from immediate‐release (IR) pramipexole to a new once‐daily extended‐release (ER) formulation. Nonfluctuating patients on pramipexole IR three‐times daily, alone or with levodopa, for early PD were randomly switched overnight to double‐blind IR three‐times daily (N = 52) or ER once‐daily (N = 104) at initially unchanged daily dosage. Successful switching (defined as no worsening >15% of baseline UPDRS II+III score and no drug‐related adverse event withdrawal) was assessed at 9 weeks, after optional dosage adjustments (primary endpoint), and at 4 weeks, before adjustment. Other secondary endpoints included adjusted mean changes from baseline in UPDRS scores and proportion of responders based on Clinical or Patient Global Impression (CGI/PGI). Absolute difference between percentage of successful switch to ER versus IR was tested for ER noninferiority, defined as a 95% confidence‐interval lower bound not exceeding −15%. At 9 weeks, 84.5% of the ER group had been successfully switched, versus 94.2% for IR. Noninferiority was not demonstrated, with a difference of −9.76% (95% CI: [−18.81%, +1.66%]). At 4 weeks, 81.6% of the ER group had been successfully switched, versus 92.3% for IR, a difference of −10.75% (95% CI: [−20.51%, +1.48%]). UPDRS changes and CGI/PGI analyses showed no differences between the groups. Both formulations were safe and well tolerated. Pramipexole ER was not equivalent to IR, but the difference was marginal. The fact that >80% of the patients successfully switched overnight at unchanged dosage shows that this practice was feasible in most patients. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.23262
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001704
Links to Exploration step
ISTEX:624285B60AB87EE65180007CBA2766EED01548AFLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy, safety, and tolerability of overnight switching from immediate‐ to once daily extended‐release pramipexole in early Parkinson's disease</title>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="1"><mods:affiliation>Departments of Clinical Pharmacology and Neurosciences, Toulouse University Hospital, INSERM CIC9302‐UMR825 Toulouse, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Departments of Clinical Pharmacology and Neurosciences, Toulouse University Hospital, INSERM CIC9302‐UMR825 Toulouse</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Departments of Clinical Pharmacology and Neurosciences, Faculty of Medicine, 37 Allées Jules Guesde, 31000 Toulouse, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Departments of Clinical Pharmacology and Neurosciences, Faculty of Medicine, 37 Allées Jules Guesde, 31000 Toulouse</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Barone, Paolo" sort="Barone, Paolo" uniqKey="Barone P" first="Paolo" last="Barone">Paolo Barone</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurological Sciences, University of Naples, Naples, Italy</mods:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Neurological Sciences, University of Naples, Naples</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Mizuno, Yoshikuni" sort="Mizuno, Yoshikuni" uniqKey="Mizuno Y" first="Yoshikuni" last="Mizuno">Yoshikuni Mizuno</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Juntendo University School of Medicine, Bunkyo‐ku, Tokyo, Japan</mods:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Neurology, Juntendo University School of Medicine, Bunkyo‐ku, Tokyo</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</mods:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, Innsbruck Medical University, Innsbruck</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Schapira, Anthony H V" sort="Schapira, Anthony H V" uniqKey="Schapira A" first="Anthony H. V." last="Schapira">Anthony H. V. Schapira</name>
<affiliation wicri:level="1"><mods:affiliation>University Department of Clinical Neurosciences, Institute of Neurology, University College London, London, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>University Department of Clinical Neurosciences, Institute of Neurology, University College London, London</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Salin, Laurence" sort="Salin, Laurence" uniqKey="Salin L" first="Laurence" last="Salin">Laurence Salin</name>
<affiliation wicri:level="1"><mods:affiliation>Clinical Research Department, Boehringer Ingelheim France S.A.S., Reims, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Clinical Research Department, Boehringer Ingelheim France S.A.S., Reims</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Sohr, Mandy" sort="Sohr, Mandy" uniqKey="Sohr M" first="Mandy" last="Sohr">Mandy Sohr</name>
<affiliation wicri:level="1"><mods:affiliation>Medical Division, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany</mods:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Medical Division, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Debieuvre, Catherine" sort="Debieuvre, Catherine" uniqKey="Debieuvre C" first="Catherine" last="Debieuvre">Catherine Debieuvre</name>
<affiliation wicri:level="1"><mods:affiliation>Clinical Research Department, Boehringer Ingelheim France S.A.S., Reims, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Clinical Research Department, Boehringer Ingelheim France S.A.S., Reims</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:624285B60AB87EE65180007CBA2766EED01548AF</idno>
<date when="2010" year="2010">2010</date>
<idno type="doi">10.1002/mds.23262</idno>
<idno type="url">https://api.istex.fr/document/624285B60AB87EE65180007CBA2766EED01548AF/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001704</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001704</idno>
<idno type="wicri:Area/Istex/Curation">001702</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Efficacy, safety, and tolerability of overnight switching from immediate‐ to once daily extended‐release pramipexole in early Parkinson's disease</title>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="1"><mods:affiliation>Departments of Clinical Pharmacology and Neurosciences, Toulouse University Hospital, INSERM CIC9302‐UMR825 Toulouse, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Departments of Clinical Pharmacology and Neurosciences, Toulouse University Hospital, INSERM CIC9302‐UMR825 Toulouse</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Departments of Clinical Pharmacology and Neurosciences, Faculty of Medicine, 37 Allées Jules Guesde, 31000 Toulouse, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Departments of Clinical Pharmacology and Neurosciences, Faculty of Medicine, 37 Allées Jules Guesde, 31000 Toulouse</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Barone, Paolo" sort="Barone, Paolo" uniqKey="Barone P" first="Paolo" last="Barone">Paolo Barone</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurological Sciences, University of Naples, Naples, Italy</mods:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Neurological Sciences, University of Naples, Naples</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Mizuno, Yoshikuni" sort="Mizuno, Yoshikuni" uniqKey="Mizuno Y" first="Yoshikuni" last="Mizuno">Yoshikuni Mizuno</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Juntendo University School of Medicine, Bunkyo‐ku, Tokyo, Japan</mods:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Neurology, Juntendo University School of Medicine, Bunkyo‐ku, Tokyo</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</mods:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, Innsbruck Medical University, Innsbruck</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Schapira, Anthony H V" sort="Schapira, Anthony H V" uniqKey="Schapira A" first="Anthony H. V." last="Schapira">Anthony H. V. Schapira</name>
<affiliation wicri:level="1"><mods:affiliation>University Department of Clinical Neurosciences, Institute of Neurology, University College London, London, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>University Department of Clinical Neurosciences, Institute of Neurology, University College London, London</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Salin, Laurence" sort="Salin, Laurence" uniqKey="Salin L" first="Laurence" last="Salin">Laurence Salin</name>
<affiliation wicri:level="1"><mods:affiliation>Clinical Research Department, Boehringer Ingelheim France S.A.S., Reims, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Clinical Research Department, Boehringer Ingelheim France S.A.S., Reims</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Sohr, Mandy" sort="Sohr, Mandy" uniqKey="Sohr M" first="Mandy" last="Sohr">Mandy Sohr</name>
<affiliation wicri:level="1"><mods:affiliation>Medical Division, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany</mods:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Medical Division, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Debieuvre, Catherine" sort="Debieuvre, Catherine" uniqKey="Debieuvre C" first="Catherine" last="Debieuvre">Catherine Debieuvre</name>
<affiliation wicri:level="1"><mods:affiliation>Clinical Research Department, Boehringer Ingelheim France S.A.S., Reims, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Clinical Research Department, Boehringer Ingelheim France S.A.S., Reims</wicri:regionArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2010-10-30">2010-10-30</date>
<biblScope unit="volume">25</biblScope>
<biblScope unit="issue">14</biblScope>
<biblScope unit="page" from="2326">2326</biblScope>
<biblScope unit="page" to="2332">2332</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">624285B60AB87EE65180007CBA2766EED01548AF</idno>
<idno type="DOI">10.1002/mds.23262</idno>
<idno type="ArticleID">MDS23262</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term>
<term>dopamine agonist</term>
<term>pramipexole‐extended release</term>
<term>switch trial</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The aim of this article is to test the feasibility, in early Parkinson's disease (PD), of an overnight switch from immediate‐release (IR) pramipexole to a new once‐daily extended‐release (ER) formulation. Nonfluctuating patients on pramipexole IR three‐times daily, alone or with levodopa, for early PD were randomly switched overnight to double‐blind IR three‐times daily (N = 52) or ER once‐daily (N = 104) at initially unchanged daily dosage. Successful switching (defined as no worsening >15% of baseline UPDRS II+III score and no drug‐related adverse event withdrawal) was assessed at 9 weeks, after optional dosage adjustments (primary endpoint), and at 4 weeks, before adjustment. Other secondary endpoints included adjusted mean changes from baseline in UPDRS scores and proportion of responders based on Clinical or Patient Global Impression (CGI/PGI). Absolute difference between percentage of successful switch to ER versus IR was tested for ER noninferiority, defined as a 95% confidence‐interval lower bound not exceeding −15%. At 9 weeks, 84.5% of the ER group had been successfully switched, versus 94.2% for IR. Noninferiority was not demonstrated, with a difference of −9.76% (95% CI: [−18.81%, +1.66%]). At 4 weeks, 81.6% of the ER group had been successfully switched, versus 92.3% for IR, a difference of −10.75% (95% CI: [−20.51%, +1.48%]). UPDRS changes and CGI/PGI analyses showed no differences between the groups. Both formulations were safe and well tolerated. Pramipexole ER was not equivalent to IR, but the difference was marginal. The fact that >80% of the patients successfully switched overnight at unchanged dosage shows that this practice was feasible in most patients. © 2010 Movement Disorder Society</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001702 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 001702 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= Istex |étape= Curation |type= RBID |clé= ISTEX:624285B60AB87EE65180007CBA2766EED01548AF |texte= Efficacy, safety, and tolerability of overnight switching from immediate‐ to once daily extended‐release pramipexole in early Parkinson's disease }}
This area was generated with Dilib version V0.6.29. |